Table 2 Patient characteristics
Characteristics | n (%) |
|---|---|
Age, y | |
 ≥ 50 | 48 (68.6) |
 < 50 | 22 (31.4) |
Gender | |
 Male | 59 (84.3) |
 Female | 11 (15.7) |
Therapeutic modalities | |
 SBRT alone | 20 (28.6) |
 SBRT+TACE | 46 (65.7) |
 SBRT+Surgery | 4 (5.7) |
Dose, Gy | |
 ≤ 35.0 | 29 (41.4) |
 ≥ 40.0 | 41 (58.6) |
Types of PVTT | |
 II | 42 (60.0) |
 III | 27 (38.6) |
 IV | 1 (1.4) |
HBsAg | |
 Negative | 12 (17.1) |
 Positive | 58 (82.9) |
Child-Pugh classification | |
 A | 45 (64.3) |
 B | 24 (34.3) |
 C | 1 (1.4) |
PS (ECOG) | |
 0 | 56 (80.0) |
 1 | 14 (20.0) |
Origination of PVTT | |
 Right branch | 49 (70.0) |
 Left branch | 21 (30.0) |
AFP, ng/L | |
 ≤ 20 | 13 (18.6) |
 21 ~ 399 | 17 (24.3) |
 ≥ 400 | 40 (57.1) |
PLT, 109/L | |
 ≥ 100 | 39 (55.7) |
 < 100 | 31 (44.3) |
HGB, g/L | |
 ≥ 120 | 42 (60.0) |
 < 120 | 28 (40.0) |
TBIL, μmol/L | |
 ≥ 20 | 34 (48.6) |
 < 20 | 36 (51.4) |
Albumin, g/L | |
 ≥ 35 | 41 (58.6) |
 < 35 | 29 (41.4) |
ALT, U/L | |
 ≥ 50 | 25 (35.7) |
 < 50 | 45 (64.3) |
AST, U/L | |
 ≥ 50 | 48 (68.6) |
 < 50 | 22 (31.4) |